Drug Combination Slows Progression of ALS and Could Mark ‘New Era’ in Treatment
September 3, 2020
A combination of two experimental drugs appears to slow the decline of patients with amyotrophic lateral sclerosis, an illness often known as ALS or Lou Gehrig’s disease.
A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team reports in the Sept. 3 issue of The New England Journal of Medicine.
A combination of two experimental drugs appears to slow the decline of patients with amyotrophic lateral sclerosis, an illness often known as ALS or Lou Gehrig’s disease.
A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team reports in the Sept. 3 issue of The New England Journal of Medicine.
The difference was modest but meaningful to patients, said Dr. Sabrina Paganoni. She’s the lead author and a researcher at the Sean Healey & AMG Center for ALS at Mass General and Harvard Medical School….